There was no collaboration revenue for Q3, compared to $1.3M for Q3 of 2023. The decrease in collaboration revenue was primarily due to activities under the Biogen Collaboration Agreement. Cash, cash equivalents, and marketable securities were approximately $1.28B as of September 30, 2024.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target raised to $45 from $40 at Jefferies
- DNLI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Denali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
- Denali Therapeutics reinstated with a Market Perform at Raymond James
- Denali Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald